Twenty AGs Issue Letter on Chinese-Sourced Ingredients in Some Compounded GLP-1s and Peptides

Twenty State Attorneys General Raise Alarms Over Chinese-Sourced Ingredients in Compounded GLP-1 Drugs

A coalition of twenty state attorneys general has issued a letter addressing concerns about Chinese-sourced active pharmaceutical ingredients (APIs) used in some compounded versions of GLP-1 receptor agonists and other peptide-based medications, according to reports. The letter adds to a growing chorus of regulatory and legal scrutiny directed at the compounding pharmacy sector, which has expanded rapidly to meet surging demand for weight-loss and diabetes drugs such as semaglutide and tirzepatide.

While full details of the letter's specific recipients and demands were not immediately available in all reporting, the action signals that state-level law enforcement officials are joining federal regulators in examining the supply chains behind compounded GLP-1 products—particularly where raw materials originate from overseas, and from China in particular.

Why Compounded GLP-1s Have Drawn Scrutiny

Compounded drugs are custom-prepared medications made by licensed pharmacies under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. These provisions allow compounding when FDA-approved drugs are in shortage, in short supply, or when a patient has a specific clinical need that commercial products cannot meet. For much of the past two years, semaglutide (marketed as Ozempic and Wegovy) and tirzepatide (marketed as Mounjaro and Zepbound) appeared on the FDA's drug shortage list, opening the door for compounding pharmacies to produce alternative versions using bulk API purchased from third-party suppliers.

That shortage designation has since been contested and, in some cases, resolved by the FDA, prompting legal battles over whether compounders may continue producing these drugs. Separately, questions have persisted about where compounders are sourcing their raw peptide material and whether that material meets the purity, potency, and safety standards required under federal law.

Chinese chemical manufacturers supply a significant share of the world's bulk pharmaceutical ingredients, including many peptides used in compounding. Industry observers and regulators have repeatedly flagged concerns that:

• Some overseas API suppliers are not registered with or inspected by the FDA
• Bulk peptide material marketed as "research use only" has reportedly entered the compounding supply chain despite not being intended for human use
• Variability in manufacturing standards abroad can lead to inconsistent potency, impurities, or contamination
• Limited traceability makes it difficult for pharmacies, regulators, and consumers to verify the provenance of ingredients

The Role of State Attorneys General

State attorneys general have increasingly positioned themselves as active participants in pharmaceutical oversight, particularly in areas touching consumer protection, unfair trade practices, and public health. A joint letter signed by twenty AGs represents a substantial bipartisan or multistate show of concern, suggesting the issue has moved beyond a narrow regulatory dispute and into the realm of consumer protection enforcement.

Attorneys general typically have authority to investigate deceptive marketing, enforce state pharmacy practice laws, and coordinate with the FDA on products that may pose risks to residents. A multistate letter of this kind often serves as a precursor to more formal action, including investigations, subpoenas, or coordinated enforcement initiatives targeting specific compounders, distributors, or ingredient suppliers.

What This Means for the Peptide and Compounding Industry

For pharmacies, telehealth platforms, and suppliers operating in the compounded GLP-1 and peptide space, this letter is a signal that scrutiny is intensifying from multiple directions at once—federal, state, and now multistate coalitions of law enforcement officials.

• Increased compliance pressure: Compounders may face heightened expectations to document API sourcing, including certificates of analysis and supplier audit trails.
• Potential state-level enforcement actions: Attorneys general could pursue investigations or litigation against companies found to be misrepresenting ingredient origin or quality.
• Reputational risk: Even absent formal charges, public attention to sourcing concerns can affect consumer trust and provider referral patterns.
• Possible legislative or regulatory follow-up: Letters of this nature sometimes precede calls for new state laws governing compounding disclosures or stricter licensing requirements for pharmacies handling peptide-based drugs.

For patients and prescribers, the letter underscores a broader message that has circulated throughout the GLP-1 compounding debate: not all compounded products are created equal, and ingredient sourcing matters significantly when it comes to safety and efficacy.

Broader Regulatory Context

This development follows a string of FDA actions targeting compounded GLP-1 products, including warnings about adverse events linked to dosing errors, salt-form variants of semaglutide not approved by the agency, and products compounded with ingredients from unregistered facilities. The FDA has also issued import alerts affecting certain foreign API manufacturers and has taken enforcement steps against compounders it determined were operating outside the bounds of 503A and 503B exemptions.

The attorneys general letter appears to build on these federal concerns while asserting a state-level interest in protecting residents from potentially substandard or mislabeled products entering the market through compounding channels.

What to Watch For

Readers and industry stakeholders should monitor several developments in the coming weeks and months:

• Whether the FDA issues a coordinated response or follow-up guidance addressing Chinese-sourced peptide APIs specifically
• Any formal investigations opened by individual state attorneys general against named compounding pharmacies or suppliers
• Potential legislative proposals at the state level requiring enhanced disclosure of ingredient origin for compounded drugs
• Industry responses from compounding pharmacy associations, which may push back on characterizations of widespread sourcing problems
• Further federal action, including possible import alerts or warning letters tied to specific overseas manufacturers

As the compounded GLP-1 market continues to navigate shifting FDA shortage determinations and litigation, this multistate letter adds another layer of regulatory complexity that pharmacies, suppliers, and prescribers will need to track closely.

This article is intended for informational purposes only and does not constitute legal or medical advice. Readers seeking guidance on compliance obligations or treatment decisions should consult qualified legal counsel or healthcare providers.